Predicting clinical outcomes using baseline and follow‐up laboratory data from the hepatitis C long‐term treatment against cirrhosis trial

Marc G. Ghany, Hae‐Young Kim, Anne Stoddard, Elizabeth C. Wright, Leonard B. Seeff, Anna S.F. Lok, the HALT‐C Trial Group – 11 July 2011 – Predicting clinical outcomes in patients with chronic hepatitis C is challenging. We used the hepatitis C long‐term treatment against cirrhosis (HALT‐C) trial database to develop two models, using baseline values of routinely available laboratory tests together with changes in these values during follow‐up to predict clinical decompensation and liver‐related death/liver transplant in patients with advanced hepatitis C.

Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12‐month randomized, prospective, open‐ label trial

Dawn M. Torres, Frances J. Jones, Janet C. Shaw, Christopher D. Williams, John A. Ward, Stephen A. Harrison – 11 July 2011 – Medication combinations that improve the efficacy of thiazolidinediones or ameliorate weight‐gain side effects of therapy represent an attractive potential treatment for (NASH). The aim of this randomized, open‐label trial was to assess the efficacy of rosiglitazone and metformin in combination versus rosiglitazone and losartan, compared to rosiglitazone alone, after 48 weeks of therapy.

Excess liver‐related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care

Hamish A. Innes, Sharon J. Hutchinson, Samuel Allen, Diptendu Bhattacharyya, Peter Bramley, Toby E.S. Delahooke, John F. Dillon, Ewan Forrest, Andrew Fraser, Ruth Gillespie, David J. Goldberg, Nicholas Kennedy, Scott McDonald, Allan McLeod, Peter R. Mills, Judith Morris, Peter Hayes, on behalf of the Hepatitis C Clinical Database Monitoring Committee.

The antiviral protein viperin inhibits hepatitis C virus replication via interaction with nonstructural protein 5A

Karla J. Helbig, Nicholas S. Eyre, Evelyn Yip, Sumudu Narayana, Kui Li, Guillaume Fiches, Erin M. McCartney, Rohit K. Jangra, Stanley M. Lemon, Michael R. Beard – 11 July 2011 – The interferon‐stimulated gene, viperin, has been shown to have antiviral activity against hepatitis C virus (HCV) in the context of the HCV replicon, although the molecular mechanisms responsible are not well understood.

Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coactivation by Bcl‐2 and Twist1: A study of hepatocellular carcinoma

Tao Sun, Bao‐cun Sun, Xiu‐lan Zhao, Nan Zhao, Xue‐yi Dong, Na Che, Zhi Yao, Yue‐mei Ma, Qiang Gu, Wen‐kang Zong, Zhi‐yong Liu – 11 July 2011 – The antiapoptotic protein Bcl‐2 plays multiple roles in apoptosis, immunity, and autophagy. Its expression in tumors correlates with tumor grade and malignancy. The recapitulation of the normal developmental process of epithelial‐mesenchymal transition (EMT) contributes to tumor cell plasticity. This process is also a characteristic of metastatic cells and vasculogenic mimicry.

Retreatment with telaprevir combination therapy in hepatitis C patients with well‐characterized prior treatment response

Andrew J. Muir, Fred F. Poordad, John G. McHutchison, Mitchell L. Shiffman, Thomas Berg, Peter Ferenci, E. Jenny Heathcote, Jean‐Michel Pawlotsky, Stefan Zeuzem, Henk W. Reesink, Geoffrey Dusheiko, Emily C. Martin, Shelley George, Robert S. Kauffman, Nathalie Adda – 11 July 2011 – Retreatment with peginterferon alpha and ribavirin (PR) offers a limited chance of sustained virologic response (SVR) in patients who did not achieve SVR with prior PR treatment.

Oxidative stress pathways in noncancerous human liver tissue to predict hepatocellular carcinoma recurrence: A prospective, multicenter study

Shinji Tanaka, Kaoru Mogushi, Mahmut Yasen, Daisuke Ban, Norio Noguchi, Takumi Irie, Atsushi Kudo, Noriaki Nakamura, Hiroshi Tanaka, Masakazu Yamamoto, Norihiro Kokudo, Tadatoshi Takayama, Seiji Kawasaki, Michiie Sakamoto, Shigeki Arii – 11 July 2011 – The prediction of cancer recurrence holds the key to improvement of the postoperative prognosis of patients. In this study, the recurrence of early‐stage hepatocellular carcinoma (HCC) after curative hepatectomy was analyzed by the genome‐wide gene‐expression profiling on cancer tissue and the noncancerous liver tissue.

Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations

Christoph Neumann‐Haefelin, Cesar Oniangue‐Ndza, Thomas Kuntzen, Julia Schmidt, Katja Nitschke, John Sidney, Célia Caillet‐Saguy, Marco Binder, Nadine Kersting, Michael W. Kemper, Karen A. Power, Susan Ingber, Laura L. Reyor, Kelsey Hills‐Evans, Arthur Y. Kim, Georg M. Lauer, Volker Lohmann, Alessandro Sette, Matthew R. Henn, Stéphane Bressanelli, Robert Thimme, Todd M. Allen – 11 July 2011 – Human leukocyte antigen B27 is associated with spontaneous viral clearance in hepatitis C virus (HCV) infection.

Subscribe to